Vaniprevir

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

A potent, selective, orally available inhibitor of HCV NS3/4A protease with Ki of 0.05 and 0.9 nM for GT1b and 2a protease, respectively.

A potent, selective, orally available inhibitor of HCV NS3/4A protease with Ki of 0.05 and 0.9 nM for GT1b and 2a protease, respectively; displays excellent selectivity against both a range of human proteases and a broad panel of pharmacologically relevant targets; has replicon EC50 of 3 and 9 nM for GT1b and 2a, respectively, has good plasma exposure and excellent liver exposure in multiple species.HCV Infection Approved

MK-7009;MK7009;MK 7009

Microbiology/Virology

HCV

HCV

Infection

HCV Infection

923590-37-8

757.94

C38H55N5O9S

>98% (HPLC)

10 mM in DMSO

CC[C@@H]1C[C@@]1(C(NS(=O)(C2CC2)=O)=O)NC([C@@H]3C[C@@H]4CN3C([C@H](C(C)(C)C)NC(OCC(C)(CCCCC5=CC=CC6=C5CN(C(O4)=O)C6)C)=O)=O)=O

Cyclopropanecarboxamide, N-[[[6-(2-carboxy-2,3-dihydro-1H-isoindol-4-yl)-2,2-dimethylhexyl]oxy]carbonyl]-3-methyl-L-valyl-(4R)-4-hydroxy-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethyl-, (12)-lactone, (1R,2R)-

(-20℃)

With Ice Pack

≥ 2 years